Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05456087 · ClinicalTrials.gov registry record · Phase 2
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
A Phase 2 study of Androgenetic Alopecia, sponsored by Zel Skin and Laser Specialists.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05456087 is a Phase 2 study of Androgenetic Alopecia that is active but no longer recruiting, run by Zel Skin and Laser Specialists. The registered enrollment target is 20 participants, below the 164-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05456087, a Phase 2 study of Androgenetic Alopecia, is active but no longer recruiting, sponsored by Zel Skin and Laser Specialists.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of using a purified botulinum toxin (Xeomin®, Merz, USA), the same injectable used to improve face wrinkles, to treat a specific type of hair loss seen in men and women not associated with scarring or other internal disease called 'pattern hair loss'. This type of hair loss is medically called 'androgenic or androgenetic alopecia'. In men it is typically called 'male pattern baldness' whereas in women it is called 'female pattern baldness' and in both cases is hereditary meaning there will be a history of relatives that describe having the same condition.
Conditions Studied
Interventions
- DRUG incobotulinumtoxin A
Study Locations (1)
Minnesota
- ZelSkin and Laser Specialists - Edina
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2024-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05456087
The ClinicalTrials.gov registry entry for NCT05456087 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 164-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (88% lower). The listed sponsor is Zel Skin and Laser Specialists, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Androgenetic Alopecia appearing as the primary indexed condition, and to 1 intervention - of which incobotulinumtoxin A is the first listed.
NCT05456087 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05456087 about?
NCT05456087 is a clinical study titled "Use of Botulinum Toxin in the Treatment of Androgenic Alopecia". The purpose of this study is to evaluate the effect of using a purified botulinum toxin (Xeomin®, Merz, USA), the same injectable used to improve face wrinkles, to treat a specific type of hair loss seen in men and women not associated with scarring or other internal disease called 'pattern hair los...
What is the current status of trial NCT05456087?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-08-12. Estimated completion is 2024-12.
What conditions does trial NCT05456087 study?
This clinical trial studies the following conditions: Androgenetic Alopecia.
What interventions are being tested in trial NCT05456087?
The interventions under investigation include: incobotulinumtoxin A (DRUG).
Who is sponsoring clinical trial NCT05456087?
This trial is sponsored by Zel Skin and Laser Specialists, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05456087 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 2
-
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
COMPLETED · Phase 2
-
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
COMPLETED · Phase 2
-
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
COMPLETED · Phase 2
-
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.